To The Moon

$Centene(CNC)$

Centene Corporation (NYSE: CNC) has long been a bellwether for the U.S. managed care industry, particularly among firms serving government-sponsored health programs like Medicaid, Medicare, and the Affordable Care Act (ACA) marketplaces. As one of the nation’s largest Medicaid managed care organizations, Centene has benefited from rising enrollment and state outsourcing of Medicaid administration.

Yet 2025 has brought renewed questions about the future of government healthcare funding and managed care margins, as well as new uncertainty surrounding the impact of President Donald Trump’s policy initiatives in his second term. Against this backdrop, Centene stock has underperformed the broader market, leaving investors to wonder: is now the time to buy, sell, or hold this healthcare giant?

In this article, we’ll examine Centene’s current fundamentals, explore how Trump administration policy changes may reshape its outlook, and weigh the risks and opportunities for investors at today’s levels.

A Leader in Managed Care — But Facing Pressure

Centene is the largest Medicaid managed care provider in the U.S., serving more than 28 million members across Medicaid, Medicare Advantage, the ACA exchanges, and military and correctional health contracts. With annual revenues exceeding $150 billion, the company is a key player in U.S. healthcare delivery.

The company’s business model hinges on efficiently managing the cost of care for low-income and vulnerable populations while earning a fixed fee from states or enrollees. For much of the past decade, Centene grew rapidly, expanding into new states and lines of business, and benefitting from the ACA’s Medicaid expansion and individual exchanges.

However, recent quarters have revealed mounting headwinds. Medical cost ratios (MCR) have ticked higher, partly due to pent-up post-pandemic demand for care and rising drug costs. Meanwhile, the so-called Medicaid “redeterminations” — states reassessing eligibility after the COVID-era pause — have led to enrollment declines in key markets.

Investors have noticed: CNC shares are down about 10% year-to-date, underperforming both the S&P 500 and the managed care index. The stock currently trades at roughly 12 times forward earnings — a discount to peers — suggesting the market is pricing in ongoing margin and policy risks.

Impact of Trump Policy: What’s at Stake

A crucial factor in Centene’s outlook is the direction of healthcare policy under the Trump administration. President Trump’s 2025 budget proposals and public statements signal a shift toward tighter Medicaid eligibility, cuts to federal Medicaid funding, and reforms to the ACA marketplaces.

Specifically:

• Medicaid Block Grants: Trump has renewed calls to replace open-ended federal Medicaid funding with capped block grants. While states could still contract with managed care organizations like Centene, overall funding growth could slow, limiting enrollment and pressuring margins.

• Work Requirements: The administration supports imposing or expanding Medicaid work requirements, which could further reduce enrollment among certain populations.

• ACA Marketplaces: Trump has reiterated his opposition to the ACA and signaled interest in rolling back subsidies and coverage mandates, potentially shrinking the exchange population where Centene has been a major player.

These policies, if enacted, would likely reduce Centene’s total addressable market, particularly in Medicaid and ACA exchanges. At the same time, the company’s expertise in low-cost care and its relationships with states may enable it to retain or even increase market share as states seek to stretch limited dollars.

On the positive side, the administration has shown interest in expanding private-sector involvement in Medicare Advantage — a market where Centene has been growing — which could partially offset pressure elsewhere.

Investors should keep in mind, however, that healthcare policy often moves slowly, and litigation and divided government may dilute or delay major changes. Nonetheless, the policy environment in 2025 looks less favorable for Medicaid-focused players like Centene than it did during the prior administration.

Recent Results: Mixed Signals

In its most recent quarterly earnings report, Centene posted revenue of $37.4 billion, up 3% year-over-year, and adjusted EPS of $2.11, beating consensus estimates. Management reaffirmed full-year guidance but cautioned that Medicaid disenrollments were running slightly ahead of expectations.

Medical cost ratios came in at 88.3%, up modestly from a year ago, reflecting higher utilization and inflationary pressures. Centene also announced a new $2 billion share repurchase authorization, signaling confidence in its long-term cash generation despite near-term challenges.

One bright spot has been Medicare Advantage, where enrollment grew 12% year-over-year. Centene is also in the process of exiting non-core businesses and focusing on its core Medicaid, Medicare, and ACA segments — moves analysts have generally applauded.

Despite these positives, analysts remain divided. Some have downgraded the stock due to policy and margin concerns, while others see the valuation as overly pessimistic.

Market Sentiment: Skepticism But Not Capitulation

On Wall Street, sentiment toward CNC has become more cautious. According to FactSet, 11 analysts rate the stock a Buy, 14 a Hold, and 2 a Sell. The average price target of $81 implies about 15% upside from current levels.

Hedge funds have trimmed positions slightly, but ownership remains relatively stable. Options activity suggests investors are hedging for downside but not aggressively shorting.

In short, the market appears to be in a “wait-and-see” mode. Investors acknowledge Centene’s strong franchise and cash flow generation but worry about structural headwinds from policy shifts, enrollment declines, and rising costs.

Risk/Reward Matrix: Centene vs. Peers

From a risk/reward perspective, Centene appeals to investors seeking undervalued exposure to U.S. healthcare with strong long-term demand drivers — but it comes with the most significant policy and margin uncertainty among peers.

At ~12x forward earnings and with a strong balance sheet, CNC’s valuation already prices in much of the risk — but patience may be required as management navigates redeterminations and a more challenging Medicaid environment.

Compared to peers:

• Investors prioritizing stability and diversification may prefer UNH despite its higher multiple.

• Those bullish on Medicare Advantage growth might favor HUM.

• Value-oriented investors willing to tolerate operational risk could consider CVS.

Verdict: Buy, Sell, or Hold?

Given the current landscape, how should investors approach Centene stock today?

• Buy: Long-term investors who believe in Centene’s ability to adapt and retain market share despite policy headwinds may view the current valuation as attractive. At 12x forward earnings and with steady free cash flow, the stock is not expensive. Medicare Advantage growth and operational efficiencies could drive earnings growth once redeterminations subside.

• Sell: Those who see prolonged pressure from Medicaid cuts, ACA marketplace contraction, and cost inflation may prefer to lock in gains and rotate into less policy-dependent healthcare names.

• Hold: For most investors, holding seems prudent at this juncture. The stock’s discounted valuation already reflects much of the risk, but visibility remains limited until the policy picture becomes clearer. Investors may wish to wait for more data on Medicaid enrollment trends and Trump’s ability to implement his healthcare agenda.

Our verdict: Hold, with a bias toward adding on weakness. The company remains fundamentally sound, and the long-term need for affordable managed care solutions will persist. However, policy uncertainty and near-term margin pressure suggest caution.

Conclusion: Key Takeaways

• Centene remains a leader in Medicaid managed care, but faces policy and cost headwinds.

• Trump administration proposals could shrink Medicaid and ACA markets, though Medicare Advantage offers an offset.

• At current valuations, much of the bad news may already be priced in.

• Operational focus, divestitures, and share buybacks demonstrate management discipline.

• Investors should monitor enrollment trends and Washington developments closely.

Centene has proven its resilience through past policy changes, and its expertise in managing care for vulnerable populations remains a competitive advantage. Yet the landscape is shifting again, and the next 12–24 months could prove challenging as the company adapts to a less supportive regulatory environment.

For investors seeking defensive exposure to U.S. healthcare, Centene still merits a place on the watchlist — but perhaps not an aggressive overweight until greater clarity emerges.

Disclaimer: I want to make it clear that I am not a financial advisor, and nothing I say is intended to be a recommendation to buy or sell any financial instrument. Additionally, it's important to remember that there are no guarantees or certainties in trading or investing, and you should never invest money that you can't afford to lose.

@Daily_Discussion @TigerPM @TigerObserver @Tiger_comments @TigerClub